- Home
- NTIP vs LGVN Comparison
NTIP vs LGVN Comparison
Compare NTIP & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- LGVN
- Stock Information
- Founded
- NTIP 1990
- LGVN 2014
- Country
- NTIP United States
- LGVN United States
- Employees
- NTIP N/A
- LGVN N/A
- Industry
- NTIP Multi-Sector Companies
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- NTIP Miscellaneous
- LGVN Health Care
- Exchange
- NTIP Nasdaq
- LGVN Nasdaq
- Market Cap
- NTIP 28.6M
- LGVN 23.4M
- IPO Year
- NTIP 1998
- LGVN 2021
- Fundamental
- Price
- NTIP $1.34
- LGVN $1.43
- Analyst Decision
- NTIP
- LGVN Strong Buy
- Analyst Count
- NTIP 0
- LGVN 3
- Target Price
- NTIP N/A
- LGVN $8.67
- AVG Volume (30 Days)
- NTIP 25.7K
- LGVN 711.7K
- Earning Date
- NTIP 08-11-2025
- LGVN 08-13-2025
- Dividend Yield
- NTIP 7.62%
- LGVN N/A
- EPS Growth
- NTIP N/A
- LGVN N/A
- EPS
- NTIP N/A
- LGVN N/A
- Revenue
- NTIP $250,000.00
- LGVN $2,225,000.00
- Revenue This Year
- NTIP N/A
- LGVN N/A
- Revenue Next Year
- NTIP N/A
- LGVN $51.48
- P/E Ratio
- NTIP N/A
- LGVN N/A
- Revenue Growth
- NTIP N/A
- LGVN 127.50
- 52 Week Low
- NTIP $1.16
- LGVN $1.14
- 52 Week High
- NTIP $1.78
- LGVN $4.94
- Technical
- Relative Strength Index (RSI)
- NTIP 62.14
- LGVN 59.84
- Support Level
- NTIP $1.20
- LGVN $1.27
- Resistance Level
- NTIP $1.30
- LGVN $1.40
- Average True Range (ATR)
- NTIP 0.06
- LGVN 0.11
- MACD
- NTIP 0.01
- LGVN 0.04
- Stochastic Oscillator
- NTIP 69.23
- LGVN 61.40
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.